Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Zasocitinib in Pediatric Moderate-to-Severe Plaque Psoriasis
jRCT2071250114Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in plaque psoriasis (5 arms), sponsored by Takeda. Primary endpoints: Part A: sPGA Clear (0) or Almost Clear (1) with ≥2-point decrease at Week 16, Part A: PASI-75 at Week 16 and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2071250114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250114.